US 12,252,482 B2
Pyrazolopyridine derivatives and uses thereof
Simone Bonazzi, Cambridge, MA (US); Jennifer Stroka Cobb, Stow, MA (US); Natalie Alysia Dales, Arlington, MA (US); Matthew James Hesse, Pittsburgh, PA (US); Rama Jain, Danville, CA (US); John Ryan Kerrigan, Wakefield, MA (US); Hasnain Ahmed Malik, Boston, MA (US); James R Manning, Emeryville, CA (US); and Pamela Yf Ting, Somerville, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Sep. 6, 2024, as Appl. No. 18/826,887.
Application 18/460,428 is a division of application No. 17/693,759, filed on Mar. 14, 2022, granted, now 11,787,785, issued on Oct. 17, 2023.
Application 18/826,887 is a continuation of application No. 18/460,428, filed on Sep. 1, 2023.
Claims priority of provisional application 63/164,130, filed on Mar. 22, 2021.
Claims priority of provisional application 63/161,139, filed on Mar. 15, 2021.
Prior Publication US 2025/0002479 A1, Jan. 2, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/14 (2006.01); A61P 7/00 (2006.01); C07D 405/14 (2006.01); C07D 417/14 (2006.01)
CPC C07D 403/14 (2013.01) [A61P 7/00 (2018.01); C07D 405/14 (2013.01); C07D 417/14 (2013.01)] 22 Claims
 
1. A compound of Formula (Ic):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, wherein:
X is selected from CH and N;
each of R2b, R2c, R2d and R2e is independently selected from hydrogen and unsubstituted C1-C3alkyl;
R2f is hydrogen;
or R2b and R2e or R2b and R2f together with the carbon atoms to which they are attached form a C1-C3alkylene bridging ring;
R3 is selected from C1-C8alkyl, C2-C6alkenyl, —SO2R4, and C1-C6haloalkyl, wherein the C1-C8alkyl and C1-C6haloalkyl are independently substituted with 0-3 occurrences of R3a;
each R3a is independently selected from C3-C10cycloalkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, a 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, C6-C10aryl, C1-C6alkoxyl, hydroxyl, and —C(═O)—NR7R8, wherein the C3-C10cycloalkyl, 4- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl and C6-C10aryl are substituted with 0-4 occurrences of R3b;
each R3b is independently selected from C1-C6alkoxyl, halo, C1-C6haloalkyl, C1-C6haloalkoxyl, C1-C6alkyl, —CN, —SO2NR7R8, —SO2R4, and hydroxyl;
R4 is selected from C3-C8cycloalkyl, C1-C6alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C6-C10aryl, wherein the C1-C6alkyl is substituted with 0-1 occurrence of R4a;
R4a is selected from C3-C8cycloalkyl, C6-C10aryl, and C1-C6alkoxyl;
R7 is selected from hydrogen and C1-C6alkyl;
R8 is selected from hydrogen and C1-C6alkyl;
or
R7 and R8 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl comprising 0-1 additional heteroatom selected from N, O, and S; and
m is 1 or 2.